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Photoactive 8-methoxypsoralen (8-MOP) levels in hu-
man and animal sera were determined by bioassay with 
Staphylococcus aureus serving as the test organism. 8-
MOP was extracted from sera with a 9:1 (V /V) ethyl 
acetate-n-hexane mixture and reconstituted in an 
aqueous medium following evaporation of the extrac-
tant. Bacterial suspensions containing extracted 8-MOP 
were irra diated for predetermined intervals with long-
wave ultraviolet light (UV A) at an intensity of 2.1 mw I 
cm2 • Cultures containing known amounts of 8.-MOP were 
u sed as standards and cytotoxicity (i.e., drug levels) 
determined by colony counts. The detection limit for 8-
MOP was 5 ng/ml with an accuracy of ± 10% above 10 
ng/ml. Concomitant de terminations of 8-MOP levels by 
high pressure liquid chromatography (HPLC) were in 
excellent agreement with the bioassay results. 
P hotochemotherapy (PUV A) for psoriasis using 8-meth-
oxypsoralen (8-MOP) and long-wave ultraviolet (UV A) irradia-
tion has been successful in alleviating clinical symptoms in 88% 
of the treated_ patients [1]. However, demonstrable interactions 
of 8-MOP with circulating lymphocytes [2-4] as well as the 
possibility . of eye lens photosensitization [5-9) raise as yet 
unanswered questions concerning the long-term effects of 
PUV A therapy. Investigation of these topics is linked in part to 
a systematic study of 8-MOP pharmacokinetics. 
A number of analytical methods have been therefore em-
ployed to estimate 8-MOP levels in biological samples, but 
disparate resul ts were reported. Thus 8-MOP levels in human 
serum determined by high pressure liquid chromatography 
were 92-146 ng/ml [10] whereas the ranges of 23-740 and 20-
700 ng/mJ were obtained _by gas-liquid [11.] and by electron 
captw·e gas chromatography [12]. Much higher, 150-4580 and 
1000-1500 ng/mJ, 8-MOP levels were detected by thin-layer 
chromatography (TLC) [13) and by TLC followed by gas chro-
matographic determinations [1 4]. These data probably reflect 
not only normal varia tion -between human subjects and phar-
macologic efficacy of the injested preparations [15,16] bu t also 
practical advantages and limitations of the respective proce-
dures. Although these techniques probably measuTe only un-
altered drug, the interference of 8-MOP metabplites with the 
analytical determinations can't be ruled out entirely [17]. 
·For these reasons tissue · levels of photoactive compounds, 
including 8-MOP, also have been estimated by the degree of 
growth in\libition of Candida albicans cultures exposed to such 
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compounds while under UV A irradiation [18-19]. However , this 
paper-disk diffusion assay, which is sensitive to the microgram 
quantities found in the tissues of experimental animals following 
dosages of 10 mg/kg or more, does not detect the much lower 
blood levels in humans receiving the standard 0.5-0.65 mg/ kg 
dose used in PUV A therapy. Since serum levels of metabolically 
unaltered, i.e., photoactive, 8-MOP are an important determi-
nant of the photochemotherapy for psoriasis, a sensitive and 
quantitative procedure for 8-MOP determination by bioassay 
was therefore developed. It is based on the photochemical 
inhibition of Staphylococcus aureus growth [20) a microorgan-
ism more sensitive to 8-MOP and UV A than Candida albicans. 
MATERIALS AND METHODS 
8-M ethoxypsoralen 
Crystalline 8-MOP (Elder Pharm.) was used to prepare stock solu-
t ions containing 32, 4.0, 0.5, and 0.0625 ILg/ml in sterile 0.2 M phosphate 
buffer at pH 7.2. 
Bioassay System 
a. Culture conditions: The stock cul ture of S. aureu.:; (ATCC #25923) 
was plated on nutrient agar (BBL Becton Dickinson & Co. ) for the 
subseq uen t isolation of colonies. Suspension cul tu,res were ini t iated by 
the inoculation of 2 ml nutrient broth (BBL). These cultures were then 
propagated in the same med ium at ambient temperatUl'e under con-
stant agitation and used from 2-72 hr later. 
Initia lly, samples of the bacterial suspension containing 10" cells/ml 
were irradiated in (i em. Petri dishes in the presence of 8-MOP a fter 
which the number of surviving organisms was coun ted in triplicate 
pour plate cultuJ'es of serial dilu tions using nu trient agar as described 
elsewhere [20]. This procedure was then modified as follows: 250 ILl of 
a bacterial suspension conta ining 105 cells/ml in phosphate buffer (pH 
7.2) was seeded in each well of a tissue cul tw-e t ray (Costal', 1.6 cm2 
surface area/well) and irradiated with long-wave ultraviolet light in the 
presence of known additions of 8-MOP for intervals ranging from 3 to 
90 min, then plated out by the addition of 750 ILl of agar to each well 
and incubated for 24 - 48 hr at 35°C in the dark. Seria l dilu tions of the 
stock bacterial suspension were also used in the preparation of titre 
standards consisting of 20 consecutive cul ture wells progressing in 1/ 4 
log units from 10° to 10" cells/well , plated out and incubated as stated. 
Determination of the relative colony counts in irradiated wells (to the 
nearest 1/4 log unit) was then performed by visual comparison to these 
titre standards. 
b. Irradiation source: A long-wave ul traviolet lamp (Ultraviolet 
Products Model XX-15 equipped with two 41 em long #50058 bulbs) 
delivering 2.1 mw/cm2 at a 14 em distance, with the primary emission 
peaks at 365-366 nm with secof!dary peaks at 313, 334, and 404 nm 
served as irradiation source. A rotating 60 rpm platform was used to 
provide mixing during irradiat ion. 
Source of Sera 
Volunteers received orally 0.6 mg/kg of 8-MOP (capsules supplied 
by E lder Pharm. and Roche Lab.). Mongrel dogs and albino rabbits 
received in travenously 5 mg/kg 8-MOP. Five 5 to 10 ml blood samples 
were collected at predetermined in tervals and allowed to clo t. Human 
and canine serum samples and control sera were stored at -10°C prior 
to their use. 
Control Procedures 
In order to determine drug extraction yields and the detection ranges 
of bioassay and HP LC, known 8-MOP addi tions were made to 20 ml 
samples of blood, plasma and serum. For this pw-pose, freshly drawn 
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unclotted huma n a nd canine bl ood was used. Rabbit blood was hepa-
rinized to prevent prema ture clotting. Serum and plasma samples were 
made at 5 ng/ ml increments over 3-300 ng/ ml range a nd drug extraction 
fo llowed by bioassay and HPLC were performed as stated. Ini t ia lly 
only fresh samples were used . However subsequ ent determinations 
indicated that freeze-thaw cycle and the resulting hemolysis had no 
effect either on the extraction yields or on the accuracy of bioassay and 
HPLC resul ts. Separate, known addition determinations performed on 
whole blood, serum and plasma were repeated again with serum and 
plasma obtained from the whole blood containing known amounts of 8-
MOP. Pooled data obtained during these experimen ts were then used 
to establish the near constancy of blood-serum, blood-plasma and 
plasma-serum ratios, thus allowing for the subsequent extrapolation of 
chug levels in any of the assayed blood compartments following 8-MOP 
determination in either plasma, serum, or the whole blood only. 
BIOASSAY AND ANALYTICAL DETERMINATIONS 
1. Bioassay 
a. The standard procedure adopted for 8-MOP bioassay in 
serum was as follows: A 1.0 ml sample of serum was added to 
a 15 ml conical centrifuge tube and 1.6 ml of ethyl acetate-n-
h exane (9:1 V / V) was layered on the top. 
b. The contents were then thoroughly shaken on a vortex 
mixer, and centrifuged at 2,000 rpin for 10 min . 
c. A 1.0 ml aliquot of the extractant layer (5/ 8 of t he tota l) 
was removed, added to a 5 ml nalgene tube and placed in a 
vacuum oven at 50°C for 1 hr to evaporate the solvent. 
d. The dessicated residue was then reconstituted in 500 pJ of 
pH 7.2 phosphate buffer and shaken on a vortex mixer . 
e. A 200 Ill aliquot was then added to a tissue culture well, 
diluted to 250 Ill with the stock bacteria l suspension, and 
irradiated for an appropriate length of time. 
f. After the addition of agar and incubation, the bactericidal 
effect of the serum extract plus UV A irradiation was determined 
by comparison with the series of titre standards. 
2. High Pressure Liquid Chromatography 
In tandem with bioassay duplicate plasma or blood samples 
were also assayed for 8-MOP levels by HPLC as described 
e lsewhere [10]. Briefly, a 1.0 ml aliquot of oxalated whole blood 
was mixed with 2.5 ml of 1 M borate buffer pH 9. Extraction 
was performed by shaking wi th 8.0 ml n-hexane/isopropanol 
(95/ 5 V / V) for 10 min on a reciprocating shaker. The samples 
were then centrifuged at 2500 rpm at 5°C. A 7.0 ml aliquot was 
dessicated at 60°C under a stream of ni trogen. The residue was 
dissolved in 100 Ill of methylene chloride/acetonitrile (95/5 VI 
V) and a suitable aliquot injected for analysis by high pressure 
liquid chromatography (HPLC). 
A Waters Model #204 liquid chromatograph was used for the 
analysis. Separation was achieved with a 0.25 m X 4.6 mm ID 
stainless steel column containing 10 !l Partisil silica gel (Whit-
man, Inc. ). The solvent, methylene chloride/acetonitrile (95/5 
V / V) , was maintained at a flow rate of 2.2 ml/ min. Detection 
was at 254 nm. Under these conditions, the retention volume of 
8-MOP was 7.7 ml. A linear calibration curve was obtained in 
the range of 5.0 to 20.0 ng 8-MOP at a sensitivity of 0.02 a. u.f.s. 
RESULTS 
Bioassay Standards 
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8-MOP Bioassay in Serum 
A marked inhibitory effect by serum proteins on 8-MOP 
bioactivity was noted during the initial studies, thus necessitat-
ing drug extraction for measurement of tota l serum or plasma 
levels. Recovery of 8-MOP from serum was determined by 
known additions to pooled human serum. By comparing the 
bactericidal effects of t he serum or plasma extracts with solu-
tions containing the th eoretically extracted amounts of 8-MOP, 
a recovery of 105 ±10% was effected at the 100 ng/ ml level. 
However, when whole blood was used, recovery of 8-MOP was 
significan tly less. To test for possible cytotoxic substances re-
covered during extraction, an appropriate number of unirra-
diated controls was prepared, but no bacterial killing was noted. 
The high 8-MOP recovery yielded optimal bioassay sensit ivity 
while minimizing recovery variance from sample to sample. 
Accuracy of 8-MOP bioassay was also determined by double 
blind, known 3-300 ng/ ml 8-MOP addi tions to pooled human 
serum. These samples were extracted and assayed using irra-
dia tion t imes of 15, 35, and 60 min . The 8-MOP levels in the 
samples were then determined from calibration plots based on 
concomitant known additions to pooled human serum (Fig la) 
and plotted aga inst the actual concentration in each sample 
(Fig 1b) . In these determinations, the errors were ±10% and 
±20% for t he levels above 10 ng/ ml and from 5 to 10 ng/ ml 
respectively. This bioassay sensit ivity of 5 ng/ ml compar es 
favorably with t he 10 ng/ ml endpoint reported for measurement 
of 8-MOP in whole blood by HPLC [13]. 
8-MOP Bioassay in Vivo 
Specificity of 8-MOP bioassay in vivo determined in serum 
or plasma extracts was addi tionally tested by the concomitant 
analysis of duplicate samples by HPLC. Comparisons of HPLC 
and bioassay results representing 3 canine and 2 rabbit blood 
samples taken at different intervals after i.v. administration of 
5 mg/ kg of 8-MOP are depicted in T a ble I while the sepamte 
determinations of 8-MOP blood/ serum or blood/ plas.ma ratios 
following in vitro known additions are shown in Table II. The 
ratios in these 2 experiments were virtually identical for each 
species, although the difference between dog and rabbit ratios 
was very marked. For direct compa1·ison of serum and plasma 
levels as determined by bioassay with whole blood concentra-
tion as determined by HPLC the serum values were multiplied 
by blood serum ratio as depicted in Table II. For example, the 
blood levels predicted from serum bioassay (serum bioassay 
level from Table I X blood/ serum ratio of 2.4 from Table II) 
and the HPLC blood levels ar e thus very close, e.g. rabbit 
levels: 270 ng/ ml serum x 2.4 = 648 ng/ ml vs. 650 ng/ ml by 
HPLC and 67 ng/ ml serum X 2.4 = 161 ng/ ml vs. 160 ng/ ml by 
HPLC. The 3 dog samples show a lower degree of correlation: 
1524 vs. 1720, 1502 vs. 1950 and 1391 vs. 1350. 
Table III shows the results of a second in vivo experiment 
involving comparison of serum bioassay to plasma HPLC levels 
for 3 additional rabbit samples taken following a 5 mg/ kg dose 
of 8-MOP. A serum/ plasma ratio close to 1 was obtained. 
In Vivo 8-MOP L evels in Human S erum 
8-MOP serum level profiles were obtained from h ealthy 
subjects following a single 0.6 mg/ kg oral dose of 8-MOP. Zero 
control blood samples were obtained and drug levels were 
monitored from 1 to 8 h1· after dosage (Fig 2) . Peak drug levels 
in the range of 100-200 ng/ ml were detected in these subjects, 
The relationship between dosage and effect of 8-MOP plus 
UV A irradiation on S. aureus cells was determined by surviva l 
counts from Petri dish pour plates of serial dilu tions. Plots of 
t hese counts were identical to the calibration curves obtained 
by visual comparison of the bactericidal effects of a series of 8-
MOP concentrations with the series of bacterial titres plated in 
a 24 well (Costar) culture tray. Irradiation-induced cellular 
death in the absence of 8-MOP was not detectable at up to 15 
minutes UV A exposw·e, reached 50% after 60 min and was 
accompanied by a minimal baseline shift of standard curves. 
No lethal effect by 8-MOP alone was detected. 
· confirming the observed peak blood levels of 92-146 ng/ rnl 
reported using HPLC on whole blood samples from 3 subjects 
given a .56 mg/ kg dose of the drug [10). Peak levels occurred 
between l'h hr and 4 homs with the exception of one peak level 
at 6 hr. 
The in vitro determination of the 8-MOP blood/ serum ratio 
for 5 human subjects (Table II) yielded a value of 0. 7, a ratio 
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2.5 5.0 10 25 50 100 250 500 
SERUM CONCENTRATION OF 8- MOP(ng / ml} 
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a- MOP CONCENTRATION ACTUAL(ng/ml) 
F IG 1. a., Calibration curves of known 8-MOP addi t ions to serum 
followed by extraction and bioassay after 15, 35, and 60 min (1.9, 4.4, 
and 7.6 J/cm") of UVA irradiation for each sample (6 ) . Unknown 
serum samples were assayed simultaneously, a nd their 8-MOP content 
determined from the calibration curves. Four of the 16 unknowns 
t reated in part b are included for illustration.(O) .Unlmown / : actual-
18.0 ng/ml; assay- 19.8 ng/ ml. Un.Jmown. 2: actual-64 ng/ ml; assay-67 
ng/ml. Un.Jmown 3: actua l-72 ng/ml; assay-76 ng/ ml. Un.hnown. 4: 
actual-160 ng/ml; assay-173 ng/ml , Assay values for unlmowns 1, 2, and 
3 are calcula ted by averaging 2 points plotted on 2 different standard 
curves; un.lmown. 4 is calculated from 1 poin t only. b, Log-log plot of 
experimentally-determined 8-MOP serum levels vs. actual drug levels 
produced by known addi tions to pooled human serum . A double-blind 
procedure .was used in preparing the unknowns, then a second series of 
known additions to serum was prepared to serve in constructing the 
calibration c-urves (par t a.). The brohen. line represents the equ ivalence 
o( actual and calculated values '\"ith .996 correlation coefficient. 
In Vivo 8-MOP Levels in Canine Serum 
The serum levels of 8-MOP in 3 dogs foUowing an intravenous 
5 mg/kg dose were moni tored fm.- up to 8 hr (Fig 3). The init ial 
rapid fall-off of the drug level to approximately 1 J.Lg/mJ was 
followed by a very gradual decline. This resul t is essentia lly 
identical to that obtained by HPLC [10]. 
DISCUSSION 
The bioassay presented here allows one to perform multiple 
determina tions of nanogram quanti ties of 8-MOP in small sam-
ples by comparative quantita tion of bac terial phototoxicity of 
unknowns wi th known 8-MOP additions. Future applications 
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of the bioassay may include the determination of other pho-
toactive psoraJen compounds such as 4, 5', 8-trimethyl-psoralen 
used in vitiligo therapy [21-23] or 5-MOP, recently used in 
PUVA therapy, thus providing a comparative basis for quanti-
tation of photoactive levels of these compounds. In addition, 
determinations of 8-MOP in other body tissues and fluids are 
possible with only minor modifica tions of the described proce-
dure. 
S ince suJ'vival curves from visual comparison to ti tre stan-
dards were identical to those obtained from plating out serial 
TABLE I. Comparison of 8-MOP serum lev.els from bioa.ssa.y to blood 
levels from. HPLC on duplicate samples" 
Blood level Serum level Ratio of blood 
from HPLC from bioas- level to serum (ng/m1) 1' say (ng/ml) level 
Rabbit Sample A 650 270 2.41 
B 160 67 2.39 
Mean ± SD 2.40 ± .01 
Dog Sample A 1720 2600 0.66 
B 1950 2300 0.85 
c 1350 1880 0.72 
Mean ± SD 0.74 ± .10 
" Blood samples of 20 ml were drawn a fter in travenous administra-
t ion of 5 mg/kg 8-MOP in dimethyl sulfoxide; 10 ml oxa lated blood 
samples were a nalyzed by HPLC, while serum from the remaining 
clotted blood was analyzed by bioassay. 
" H PLC analyses were performed by Litton Bionetics, Rockville, Md. 
TABLE II. R a.tio.s of 8-MOP blood level to serum or plasma level 
following /mown additions to whole blood" 
8-MOP blood 8-MO P plasma Ratio of blood 
level (ng/ml)'' level (ng/ml )1' level to plasma level 
Rabbit 1 200 105 1.90 
2 200 65 3.08 
3 200 93 2. 15 
4 200 78 2.56 
Mean ± SD 2.4 ± .5 
Dog 1 1000 1480 0.68 
2 1000 1450 0.69 
3 1000 1220 0.82 
Mean ± SD 0.73 ± .08 
Human 1 80 109 0.74 
2 80 112 0.71 
3 80 128 0.63 
4 80 108 0.74 
5 80 115 0.69 
M ean± S.D. 0.70 ± .05 
" Known additions were made to unclotted, freshly-drawn whole 
blood. In the case of rabbi ts, blood was heparinized to prevent prema-
ture clott ing, and plasma instead of serum was obtained. 
" Indicated blood levels were produced by known addi t ions; Serum 
or plasma 8-MOP levels were measured by bioassay . 
TABLE Ill. Comparison of 8-MOP serum levels from bioassay to 
plasma. levels from HPLC on duplicate samples" 
R abbi t 
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1.1 ± .2 
"Blood and plasma samples (by hepariniza tion) were obta ined at 
interva ls following in travenous administration of 5 mg/kg 8-MOP in 
dimethyl sulfoxide, fTozen, and analyzed by HPLC. Serum was a nalyzed 
by bioassay. 
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FIG 2. 8-MOP serum concentration vs. time after ad ministration of 
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FIG 3. 8-MOP serum concentration vs. t ime afte r adm inistration of 
a 5 mg/kg in travenous dose of 8-MOP (in dimethyl sulfoxide) to 3 dogs. 
dilutions a nd colonies coun ts, the equivalence of t hese two 
techniques, as well as th e demonstra ble accuracy ofth e bioassay 
procedure (Fig lb) seemingly con finns the val idi ty of th e rapid 
visual compa1·ison as a means for determining relative titres 
over a range of several magnitudes. 
T h e specificity of th e bioassay is supported fmth er by t he 
agreemen t of 8-MOP blood levels predicted from bioassay with 
those determined co ncw-rently by HPLC (Tables I and III), 
and th e agreement between bioas ay and HPLC on spli t plasma 
samples (Table III) , and nearly ide ntical fall-off curves obtained 
by bioassay (Fig 2 and 3) and by HPLC as reported else-
where.[lO] The absence of s ignificant cytotoxicity by control 
serum extracts provides additional evidence of b ioassay speci-
ficity. 
The intervals between th e ingestion and peak drug levels in 
most of the subjects in t his study were in agreement with the 
1 % to 3-hr period of maximum skin photoreactivity as reported 
by Path ak et aJ [24] following t h e same oral dosage (.6 mg/ kg) 
of 8-MOP. However, t h e peak drug level of one serum profile 
occw-red six hours after ingestion . Such variation supports t h e 
suggestion [13] that PUV A therapy may be most effective if 
irradiation is performed when 8-MOP serum levels a re highest. 
While it is highly probable that skin levels follow serum levels 
closely, such a correlation shou ld be more firmly establis hed by 
concurrent assays of serum and .skin drug levels. 
Striking differences in t h e blood serum 8-MOP ratio noted in 
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rabbits as compared to dogs a nd humans (2.4 vs .. 73 a nd .70) 
may indicate a strong preferentiai8-MOP binding by rabbi t red 
blood cells. This finding a lso serves as a reminder t hat the 
bioavailability of natura lly occu rring compounds may be phy-
logenetically determined , thus necessitating t h e measurement 
of comparable serum drug levels before accepting as clinically 
significant even the most car efully compiled evidence from 
animal studies. 
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